Overview
Public BiotechPhase 4LSDketaminepsilocybin
Clinical-stage biopharma developing SLS-002, an intranasal racemic ketamine for acute suicidal ideation in depression. FDA Fast Track designation granted. Also developing treatments for ALS and Parkinson's.
Visit WebsiteNew York, NY
$30M
Market Cap
2016
Founded
0
Open Roles
Open Positions
No open positions at this time
Clinical Pipeline(4)
Unknown·N/A·LSD
Investigating Lysosomal Storage Diseases in Minority Groups
Lysosomal Storage Disorders
Not Yet Recruiting·Phase 4·ketamine
An Exploratory Study of the Efficacy and Safety of Esketamine and Dexmedetomidine in Non-Intubated ICU Patients With Hyperactive Delirium
Esketamine combined with dexmedetomidineDexmedetomidine
Unknown·Phase 4·ketamine
Effect of Esketamine on Abdominal Pain During TACE-HAIC in Patients With Hepatocellular Carcinoma
EsketamineHepatocellular Carcinoma
Unknown·Early Phase 1·psilocybin
A Community of Practice Program With Psilocybin-assisted Therapy for End-of-Life Patients
Psilocybin-assisted therapy within a community of practice model (group administered)End of Life